Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward

Opdivo and Eliquis were the usual suspects driving Bristol-Myers Squibb's growth in Q2 2017. There were no real surprises, but the recent Mystic trial results from AstraZeneca put Opdivo's current trials under more scrutiny, and that's what we expect the market to track going forward.